AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

When pondering which healthcare stock to invest in for 2026, two prominent biopharmaceutical companies, AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY), present contrasting financial trajectories to consider. AbbVie, a global leader in the pharmaceutical industry, is actively expanding its presence in immunology and aesthetics sectors.

The company's recent financial performance, as reported in its FY 2025 annual report, underscores its focus on immunology, neuroscience, and oncology, with Skyrizi and Rinvoq contributing to 42% of total net revenues. AbbVie's sales channels are heavily reliant on key distributors such as McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Corp (NYSE:COR), which account for nearly all of its U.S. pharmaceutical sales, hence introducing a significant risk due to customer concentration.

However, in 2026, AbbVie's strategic acquisition of Apogee Therapeutics signals a proactive approach to future growth and innovation.

Conversely, Bristol Myers Squibb, another behemoth in the healthcare sector, differentiates itself by leveraging an extensive oncology and hematology portfolio, which facilitates a robust cash flow for its shareholders. The company's FY 2025 annual report highlights its ability to generate steady income from its diverse range of treatments.

Despite its strengths, Bristol Myers Squibb also faces challenges, primarily centered around its customer base concentration, as it predominantly sells its products through large distributors. This reliance on a few major distributors poses a risk similar to that faced by AbbVie, albeit with distinct operational nuances. In evaluating these two healthcare giants for investment in 2026, investors must weigh the company's emphasis on growth strategies, product portfolios, and the associated risks of customer reliance.